Roberts D M, Fraser J F, Buckley N A, Venkatesh B
Australian National University Medical School, Australian Capital Territory.
Anaesth Intensive Care. 2005 Aug;33(4):469-76. doi: 10.1177/0310057X0503300408.
There is limited information regarding the management and outcomes of patients presenting with anticholinesterase pesticide poisoning in Australia. Patients presenting to a tertiary referral hospital with anticholinesterase exposures were identified by discharge coding. The medical records of each patient were retrospectively reviewed. Based on clinical outcome, patients were classified as severe or non-severe poisonings. Forty-one presentations were noted between 1990 and 2003. Eight patients (20%) had severe poisoning of which tachycardia, fasciculations with weakness and metabolic acidosis were common manifestations. The diagnosis was delayed in four patients due to the absence of a clear history, which did not influence patient outcomes or put hospital staff at risk of nosocomial poisoning. The median length of hospital stay was prolonged in severe poisonings (20 days) compared to 12 hours in other patients. Two cases of intermediate syndrome were attributed to fenthion and diazinon, and one case of delayed polyneuropathy to trichlorfon. Cholinesterase activities were performed in only 49% of presentations. The overall mortality was 2.4% (1 death) and the mortality in patients with severe poisoning was 12.5%. The incidence of anticholinesterase poisoning in Australia is low. These outcomes were favourable and comparable with other published data. Measures to enhance the knowledge of medical staff supplemented by validated treatment protocols should be developed. For less significant exposures, an emphasis on adequate documentation of cholinergic signs and cholinesterase activities is necessary for rapid triage and may also have potential forensic implications if not performed.
在澳大利亚,关于抗胆碱酯酶农药中毒患者的管理及治疗结果的信息有限。通过出院编码识别出在三级转诊医院就诊的抗胆碱酯酶暴露患者。对每位患者的病历进行回顾性审查。根据临床结果,将患者分为重度或非重度中毒。1990年至2003年间共记录了41例病例。8例(20%)患者为重度中毒,心动过速、伴有肌无力的肌束震颤和代谢性酸中毒是常见表现。4例患者因病史不明导致诊断延迟,但这并未影响患者的治疗结果,也未使医院工作人员面临医院感染中毒的风险。与其他患者的12小时相比,重度中毒患者的中位住院时间延长(20天)。两例中间综合征归因于倍硫磷和二嗪农,一例迟发性多发性神经病归因于敌百虫。仅49%的病例进行了胆碱酯酶活性检测。总体死亡率为2.4%(1例死亡),重度中毒患者的死亡率为12.5%。澳大利亚抗胆碱酯酶中毒的发病率较低。这些结果是令人满意的,与其他已发表的数据相当。应制定措施,通过有效的治疗方案来提高医务人员的知识水平。对于不太严重的暴露情况,强调充分记录胆碱能体征和胆碱酯酶活性对于快速分诊是必要的,如果不这样做,可能还会有潜在的法医意义。